Blog | BioInformant

Athersys’ MultiStem® Therapy for COVID-19 Designated “Highly Relevant” by BARDA

April 2, 2020 By Cade Hildreth, Founder & President 1 Comment

Headquartered in Cleveland, Ohio, Athersys is a biotech company focused on the development of novel cell therapeutics. With acute respiratory distress syndrome (ARDS) identified as a leading cause of death in COVID-19 patients, Athersys is working fast to launch a pivotal trial of its MultiStem® cell therapy product for the treatment of this life-threatening condition. [Read more…]

Pluristem Treated First Three COVID-19 Patients in Israel under Compassionate Use

April 2, 2020 By Cade Hildreth, Founder & President 2 Comments

Pluristem Therapeutics expects to treat more patients in Israel in the near future
It is in discussions with regulatory agencies in the U.S. and Europe to define its clinical strategy for COVID-19

[Read more…]

Stem Cell Researchers Use AI to Help Improve Regenerative Medicine

March 30, 2020 By Cade Hildreth, Founder & President Leave a Comment

Medicine and technology can work together to produce amazing results. One of the most promising ‘marriages’ is that involving stem cell research and artificial intelligence (AI). Researchers are attempting to use AI to aid and augment stem cell technologies. How can machine learning play a role in restorative medicine? [Read more…]

Promising Drugs, Antibodies, and Vaccines in Development Against COVID-19

March 28, 2020 By Cade Hildreth, Founder & President Leave a Comment

What are the most promising drugs, antibodies, and vaccines in development against COVID-19? Our team sifted through hundreds of articles and research papers to identify the most promising ones. In most cases, these drugs, vaccines and antibodies are already in use for other diseases, making it easier to leverage them in the fight against the Coronavirus. [Read more…]

AlloVir & Baylor College of Medicine to Develop Allogeneic T-Cell Therapies for COVID-19

March 26, 2020 By Cade Hildreth, Founder & President Leave a Comment

AlloVir’s proprietary technology is designed to develop virus specific T-cell therapies with potential to treat and prevent several devastating viral diseases with each single cell therapy product.

CAMBRIDGE, Mass & HOUSTON- AlloVir, a late-clinical stage T-cell immunotherapy company, today announced the expansion of its research and development collaboration with Baylor College of Medicine to include the discovery and development of allogeneic, off-the-shelf, virus specific T-cell therapies to combat SARS-CoV-2, the virus that causes COVID-19. [Read more…]

Pluristem Therapeutics expects to treat more patients in Israel in the near future

It is in discussions with regulatory agencies in the U.S. and Europe to define its clinical strategy for COVID-19

AlloVir’s proprietary technology is designed to develop virus specific T-cell therapies with potential to treat and prevent several devastating viral diseases with each single cell therapy product.